They are applied under the “urgency” protocol. Two experimental vaccines from Sinopharm are being used.
About a million people have already been inoculated “urgently” with two experimental vaccines against the new coronavirus from the Chinese firm Sinopharmsaid the pharmaceutical company on Friday without providing clinical data on its effectiveness. No serious side effects have been detected either.
The president of the company, Liu Jingzhen, assured that to date “only a few” people have shown “mild symptoms” after receiving the vaccine, according to a statement posted by Sinopharm on Wechat.
The vaccination is part of an emergency program with which Beijing has already begun to immunize strategic sectors. The official media have been reporting vaccinations to health workers, military, diplomats and other officials for weeks.
The Sinopharm vaccine has now completed phase three trials following work on a total of ten countriesincluding the United Arab Emirates, Bahrain, Egypt, Jordan, Peru and Argentina.
China authorized last boreal summer (winter in Argentina) the inoculations of these vaccines not yet approved for cases considered urgent, such as employees and students traveling abroad or highly exposed workers, such as medical personnel.
“Our vaccines were inoculated to about a million people and we had no comments of serious unwanted reactions,” Liu Jingzhen, the president of Sinopharm, said on the group’s website.
According to the company, none of the people inoculated with their vaccines caught Covid-19 despite the fact that they traveled to “more than 150 countries”.
China, where the new coronavirus was first discovered in late 2019, currently counts with four vaccines in phase 3 of trials, the last stage before a possible homologation, reported the AFP news agency.
As coronavirus patients are very few in the Asian country, despite the fact that the pandemic originated there almost a year ago, which controlled the outbreak of the disease last spring (autumn in Argentina), the tests are carried out held abroad.